Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 55 of 573 for:    Genetic AND SNP

Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02220387
Recruitment Status : Completed
First Posted : August 19, 2014
Last Update Posted : October 6, 2015
Sponsor:
Collaborator:
Siberian Branch of the Russian Academy of Medical Sciences
Information provided by (Responsible Party):
Liubov A Shpagina, Novosibirsk City Hospital #2

Brief Summary:
The objective of this study is to investigate molecular, cytological and genetic features of occupational chronic obstructive pulmonary disease (COPD) in conditions of different occupational exposures. In order to achieve this goal serum pro-inflammatory cytokines and standard inflammation markers level, hemostasis, cytological analysis of bronchoalveolar lavage and associations of single nucleotide polymorphisms (SNPs) rs1800470 transforming growing factor β1 (TGF β1) gene, rs1828591 hedgehog interacting protein (HHIP) gene, rs4129267 interleukin 6 receptor (IL-6R) gene, rs1051730 nicotinic acetylcholine receptor 3 (CHRNA3) gene with COPD in subjects exposed to silica dust and in those exposed to polycyclic aromatic hydrocarbons exhaust will be investigated. The relationship between genotype and phenotype characteristics, such as an inflammation activity, assessed by C-reactive protein (hsCRP) and tumor necrosis factor-α (TNF α) serum concentration, in different occupational COPD groups will be studied. The hypothesis is that the mechanisms underlying disease development and progression are different due to environmental risk factor that reflex in differs in disease attributes - molecular biomarkers, cytology results and genetic susceptibility between COPD due to dust, COPD due to chemicals and COPD in smokers therefore COPD can be subdivided into ecological phenotypes according to environmental risk factor.

Condition or disease Intervention/treatment
Chronic Obstructive Pulmonary Disease Other: exposure to respirable silica dust Other: exposure to polycyclic aromatic hydrocarbons exhaust

Detailed Description:

Study rationale: The main risk factors of COPD are tobacco smoking, biomass smoking and occupational factors. Tobacco smoking is well-known risk factor so tobacco induced COPD is completely established. Nevertheless the meaning of occupational factors which are less famous are equally important. Based on comprehensive literature review American Thoracic Society (ATS) endorsed the notion that strong evidence implicates occupational factors as cause of COPD [Eisner MD et al., 2010]. Occupational COPD takes 19.2 % of all COPD patients and 31.1 % of never smokers as resulted NHANESIII study [Hnizdo E. et al., 2004]. A considerable number of work-related factors have evidence for a causal association with COPD including (and of course not limited) silica and silicates and polycyclic aromatic hydrocarbons. Individuals in a variety of occupations and industries such as coal miners, coke workers, tunnel workers, metallurgists, welding workers, transportation workers, builders, farmers are exposed to factors cited above. Despite this the clinical and pathophysiological features of COPD caused by occupational factors are still unclear.

Occupational factors leading airflow limitation are various entities - vapors, dusts, gases and fumes with different physical, chemical, biological and other features, so the mechanisms underlying disease development and progression may be different attributable to risk factor.

An environmental risk factors exposure as well as tobacco smoking results in COPD only in part of the subjects which indicates the significant genome and gene environmental interactions role. COPD develops in predisposed subjects undergoing risk factors exposure. Therefore the risk of COPD is individual and depends on both genetic and environments. There are few data concerning the effects of genetic on COPD risk in this specific subgroup - people who are exposed to occupational risk factors related to the certain environmental factor.

Statistical analysis: Statistical analysis will be carried out by Statistica 9.0 software. Significance level will be considered p = 0.05. The qualitative variables will be expressed as counts and percentages. The quantitative continuous variables will be expressed as means and standard error of means (M ± m) for variables that meet the criteria of normality and minimum and maximum, median for those that do not meet the criteria of normality. Kruskal-Wallis test will be used for comparing multiply independent samples and Mann-Whitney U test for comparing two independent samples if variable under consideration will continuous and that it will be measured on an ordinal scale. For comparisons of proportions, the Chi-square will be used.

For associations assessment logistic regression method will be used. The odds ratio (OR) and 95% confidence interval (CI) will be calculated for each professional group. Multiple regression model will be used to explore the relationships between demographic characteristics, cytokine concentrations, hemostasis and airflow limitation in professional groups.


Layout table for study information
Study Type : Observational
Actual Enrollment : 352 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Molecular, Cytological Features and Genetic Susceptibility of Occupational Chronic Obstructive Pulmonary Disease Attributable to Different Environmental Exposures
Study Start Date : August 2014
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Group/Cohort Intervention/treatment
occupational COPD

Consists of 2 subgroups

  1. COPD patients with history of exposure to respirable silica dust
  2. COPD patients with history of exposure to polycyclic aromatic hydrocarbons exhaust
Other: exposure to respirable silica dust
History of exposure to respirable silica dust due to job

Other: exposure to polycyclic aromatic hydrocarbons exhaust
history of exposure to polycyclic aromatic hydrocarbons exhaust due to job

smokers with COPD and healthy control

Consists of 2 subgroups

  1. patients with COPD, history of tobacco smoke and no history of occupational exposure
  2. healthy subjects



Primary Outcome Measures :
  1. Association of SNPs rs1800470 TGF β1 gene, rs1828591 HHIP gene, rs4129267 IL-6R gene, rs1051730 CHRNA3 gene with COPD in subjects exposed to dust and in those exposed to chemicals. [ Time Frame: 1 day (a single measurement) ]
    Odds ratio and 95% confidence interval will be calculated for each occupational group. Controls - healthy people.

  2. Difference in cytological analysis of bronchoalveolar lavage fluid results between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  3. Difference in serum interleukin 1 beta (IL-1β) level between COPD patients exposed to dust, chemicals and tobacco smoke. [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  4. Difference in serum TNFα level between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  5. Difference in spontaneous thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  6. Difference in collagen induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  7. Difference in epinephrine induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  8. Difference in adenosine diphosphate induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  9. Difference in fibrinogen level between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  10. Difference in fibrinogen degradation products level between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  11. Difference in D-dimer level between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  12. Difference in serum endothelin1 level between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.

  13. Difference in serum nitric oxide level between COPD patients exposed to dust, chemicals and tobacco smoke [ Time Frame: 1 day (a single measurement) ]
    Comparison of groups.


Secondary Outcome Measures :
  1. Relationship between genotype and phenotype characteristics, such as an inflammation activity, assessed by hsCRP and TNF α serum concentration, in different occupational COPD groups. [ Time Frame: 1 day (a single measurement) ]
    For SNPs that will occur associated with occupational COPD differences in hsCRP and TNFα serum concentration between subjects with different genotypes will be established separately for exposed to dust COPD group and for exposed to chemicals COPD group.


Biospecimen Retention:   Samples With DNA
whole blood, serum,bronchoalveolar lavage fluid


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Residents of a certain town (Novosibirsk, Russian Federation)
Criteria

Inclusion Criteria:

  • Post- bronchodilator forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio less than 0.7
  • Stable phase of COPD
  • History of exposure to respirable silica dust, nonsmokers with absence of passive exposure to tobacco smoke or history of exposure to polycyclic aromatic hydrocarbons exhaust, nonsmokers with absence of passive exposure to tobacco smoke or current tobacco smokers without history of occupational exposure
  • COPD risk factor exposure (occupational or tobacco smoke) duration not less than 12 months
  • Male
  • Caucasian
  • Age of 40 - 75 years old
  • Control group - healthy people

Exclusion Criteria:

  • history of biomass smoke exposure
  • age less than 40 and above 75 years old
  • current COPD exacerbation
  • concomitant asthma
  • tuberculosis and other pulmonary diseases
  • allergic and autoimmune disorders
  • active infections
  • immunodeficiency, including HIV infection
  • parasitological diseases
  • malignancies
  • lack of informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02220387


Locations
Layout table for location information
Russian Federation
Novosibirsk City Hospital #2
Novosibirsk, Russian Federation, 630084
Sponsors and Collaborators
Novosibirsk City Hospital #2
Siberian Branch of the Russian Academy of Medical Sciences
Investigators
Layout table for investigator information
Principal Investigator: Liubov Shpagina, PhD Novosibirsk Citi Hospital #2, Novosibirsk State Medical University

Layout table for additonal information
Responsible Party: Liubov A Shpagina, Prof., Dr, Novosibirsk City Hospital #2
ClinicalTrials.gov Identifier: NCT02220387     History of Changes
Other Study ID Numbers: 01201463369/1
01201463369 ( Other Identifier: Education and Science Ministry of Russian Federation )
First Posted: August 19, 2014    Key Record Dates
Last Update Posted: October 6, 2015
Last Verified: October 2015

Keywords provided by Liubov A Shpagina, Novosibirsk City Hospital #2:
occupational COPD
phenotype
genetic

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Disease Susceptibility
Genetic Predisposition to Disease
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes